IMPORTANT SAFETY INFORMATION FOR PATIENTS

What should I discuss with my healthcare provider before taking REZZAYO®?

Before starting REZZAYO®, tell your healthcare provider about all of the medications you are taking and all of your medical conditions, including if you are allergic to rezafungin or other antifungal drugs called echinocandins.

What is the most important information I need to know about taking REZZAYO®?

• You may experience certain reactions when you are receiving REZZAYO® in the IV, including flushing, warm sensations, hives, nausea, or tightness in the chest. If these reactions occur, tell your healthcare provider. They may slow or stop the IV.
• Photosensitivity: REZZAYO® may cause you to be more sensitive to sunlight. While taking REZZAYO®, protect yourself from sun exposure and other sources of ultra-violet (UV) radiation.
• In the clinical trials for REZZAYO®, some patients had abnormal liver tests. Your healthcare provider will monitor you if you develop abnormal liver tests and decide whether you should keep taking REZZAYO®.

When should I NOT take REZZAYO®?

You should not take REZZAYO® if you are allergic to rezafungin or other antifungal drugs called echinocandins.

What are some of the most common side effects of REZZAYO®?

Most common side effects of REZZAYO® are fever, diarrhea, anemia, vomiting, nausea, stomach pain, constipation, and low levels of potassium, magnesium, or phosphate in the blood.

What is REZZAYO® (rezafungin for injection)?

REZZAYO® is an antifungal medication that treats invasive candidiasis, which is an infection of the bloodstream or internal organs caused by a yeast (a type of fungus) called Candida. It is given once-weekly through the vein (intravenous or IV).

REZZAYO® is approved for use in patients 18 years of age and over who have limited or no alternative options for the treatment of their infection. FDA approval of REZZAYO® was based on limited clinical safety and efficacy data. REZZAYO® was not studied in patients with Candida infections in the heart, bone, or brain.

Please see full Prescribing Information for additional safety information.

©2024 Melinta Therapeutics, LLC  
All rights reserved.
05/2024    PP-REZ-US-0293